245 related articles for article (PubMed ID: 34999249)
1. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.
Ju S; Wang W; Chen P; Li F; Li H; Wang M; Han X; Ren J; Duan X
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101859. PubMed ID: 34999249
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
Li N; Chen J
Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
[TBL] [Abstract][Full Text] [Related]
3. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
4. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of raltitrexed-eluting CalliSpheres
Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
[TBL] [Abstract][Full Text] [Related]
6. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres
Zhang X; Lin X; Qiu H; Peng Z
J Clin Lab Anal; 2019 Oct; 33(8):e22975. PubMed ID: 31328832
[TBL] [Abstract][Full Text] [Related]
7. Apatinib plus drug-eluting bead transarterial chemoembolization as bridging therapy to surgical resection displays an acceptable efficacy and safety profile in hepatocellular carcinoma patients.
Yan J; Sun Y; Fan D; Mu W
Indian J Cancer; 2023 Oct; 60(4):562-569. PubMed ID: 36861729
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma.
Hu Y; Hao M; Chen Q; Chen Z; Lin H
Am J Transl Res; 2020; 12(10):6584-6598. PubMed ID: 33194055
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
[TBL] [Abstract][Full Text] [Related]
10. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients.
Zhu D; Yuan D; Wang Z; Chen S
Medicine (Baltimore); 2019 Jun; 98(26):e15682. PubMed ID: 31261491
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma.
Chen S; Yu W; Zhang K; Liu W
BMC Cancer; 2018 Nov; 18(1):1131. PubMed ID: 30453925
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma.
Liu S; Liu KC; Lv WF; Lu D; Zhu XH; Jiang B; Tan YL; Wang GX
Front Med (Lausanne); 2021; 8():774345. PubMed ID: 34970563
[No Abstract] [Full Text] [Related]
16. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma.
Zhang W; Chen L; Cao Y; Sun B; Ren Y; Sun T; Zheng C
Cancer Manag Res; 2021; 13():5391-5402. PubMed ID: 34262347
[TBL] [Abstract][Full Text] [Related]
18. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Li C
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101535. PubMed ID: 33121882
[TBL] [Abstract][Full Text] [Related]
19. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
